Literature DB >> 20617898

Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin.

Tian Lin1, Young Ho Kwak, Fatima Sammy, Ping He, Sujatha Thundivalappil, Guangjie Sun, Wei Chao, H Shaw Warren.   

Abstract

Detection of microbial components by immune cells via Toll-like receptors (TLRs) with subsequent induction of inflammation is essential for host defense. However, an overactive immune response can cause tissue damage and sepsis. The endogenous molecule hemoglobin and its derivative heme are often released into tissue compartments where there is infection in the presence of degrading blood. We found that hemoglobin synergizes with multiple TLR agonists to induce high levels of tumor necrosis factor and interleukin-6 from macrophages and that this synergy is independent of TLR4 and MyD88. In contrast, heme synergized with some but not all TLR agonists studied. Furthermore, the synergy of both hemoglobin and heme with lipopolysaccharide was suppressed by hemopexin, a plasma heme-binding protein. These studies suggest that hemoglobin and heme may substantially contribute to microbe-induced inflammation when bacterial or viral infection coexists with blood degradation and that hemopexin may play a role in controlling inflammation in such settings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20617898      PMCID: PMC2932749          DOI: 10.1086/654929

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

Review 1.  Toll-like receptors: critical proteins linking innate and acquired immunity.

Authors:  S Akira; K Takeda; T Kaisho
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

2.  MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists.

Authors:  Aranya Bagchi; Elizabeth A Herrup; H Shaw Warren; James Trigilio; Hae-Sook Shin; Catherine Valentine; Judith Hellman
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

Review 3.  Gating the radical hemoglobin to macrophages: the anti-inflammatory role of CD163, a scavenger receptor.

Authors:  Dominik J Schaer; Abdu I Alayash; Paul W Buehler
Journal:  Antioxid Redox Signal       Date:  2007-07       Impact factor: 8.401

Review 4.  Nitric oxide and the immune response.

Authors:  C Bogdan
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

5.  The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells.

Authors:  M F Roelofs; L A B Joosten; S Abdollahi-Roodsaz; A W T van Lieshout; T Sprong; F H van den Hoogen; W B van den Berg; T R D J Radstake
Journal:  Arthritis Rheum       Date:  2005-08

Review 6.  Hemopexin: structure, function, and regulation.

Authors:  Emanuela Tolosano; Fiorella Altruda
Journal:  DNA Cell Biol       Date:  2002-04       Impact factor: 3.311

7.  Synergy of CpG oligodeoxynucleotide and double-stranded RNA (poly I:C) on nitric oxide induction in chicken peripheral blood monocytes.

Authors:  Haiqi He; Kenneth J Genovese; David J Nisbet; Michael H Kogut
Journal:  Mol Immunol       Date:  2007-03-06       Impact factor: 4.407

8.  Enhancement of macrophage stimulation by lipoteichoic acid and the costimulant hemoglobin is dependent on Toll-like receptors 2 and 4.

Authors:  Kathleen H Cox; Itzhak Ofek; David L Hasty
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

9.  Resilience to bacterial infection: difference between species could be due to proteins in serum.

Authors:  H Shaw Warren; Catherine Fitting; Eva Hoff; Minou Adib-Conquy; Laura Beasley-Topliffe; Brenda Tesini; Xueya Liang; Catherine Valentine; Judith Hellman; Douglas Hayden; Jean-Marc Cavaillon
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

10.  Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria.

Authors:  Ana Pamplona; Ana Ferreira; József Balla; Viktória Jeney; György Balla; Sabrina Epiphanio; Angelo Chora; Cristina D Rodrigues; Isabel Pombo Gregoire; Margarida Cunha-Rodrigues; Silvia Portugal; Miguel P Soares; Maria M Mota
Journal:  Nat Med       Date:  2007-05-13       Impact factor: 53.440

View more
  39 in total

1.  Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation.

Authors:  Tian Lin; Fatima Sammy; Huan Yang; Sujatha Thundivalappil; Judith Hellman; Kevin J Tracey; H Shaw Warren
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

Review 2.  Mechanisms of Hemolysis During Sepsis.

Authors:  Katharina Effenberger-Neidnicht; Matthias Hartmann
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

Review 3.  Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies.

Authors:  Dominik J Schaer; Paul W Buehler
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

4.  Identification of oxidative modifications of hemopexin and their predicted physiological relevance.

Authors:  Peter Hahl; Rachel Hunt; Edward S Bjes; Andrew Skaff; Andrew Keightley; Ann Smith
Journal:  J Biol Chem       Date:  2017-06-08       Impact factor: 5.157

5.  Imaging flow cytometry for automated detection of hypoxia-induced erythrocyte shape change in sickle cell disease.

Authors:  Eduard J van Beers; Leigh Samsel; Laurel Mendelsohn; Rehan Saiyed; Kleber Y Fertrin; Christine A Brantner; Mathew P Daniels; James Nichols; J Philip McCoy; Gregory J Kato
Journal:  Am J Hematol       Date:  2014-04-12       Impact factor: 10.047

Review 6.  A perspective on the role of extracellular hemoglobin on the innate immune system.

Authors:  Sae Kyung Lee; Jeak Ling Ding
Journal:  DNA Cell Biol       Date:  2012-12-18       Impact factor: 3.311

Review 7.  Inflammatory targets of therapy in sickle cell disease.

Authors:  Amma Owusu-Ansah; Chibueze A Ihunnah; Aisha L Walker; Solomon F Ofori-Acquah
Journal:  Transl Res       Date:  2015-07-11       Impact factor: 7.012

Review 8.  Role of hemoglobin/heme scavenger protein hemopexin in atherosclerosis and inflammatory diseases.

Authors:  Niyati U Mehta; Srinivasa T Reddy
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

9.  Purified and Recombinant Hemopexin: Protease Activity and Effect on Neutrophil Chemotaxis.

Authors:  Tian Lin; Jialin Liu; Feng Huang; Tjitske Sr van Engelen; Sujatha R Thundivalappil; Frank E Riley; Michael Super; Alexander L Watters; Ann Smith; Nathan Brinkman; Donald E Ingber; H Shaw Warren
Journal:  Mol Med       Date:  2016-01-08       Impact factor: 6.354

Review 10.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.